A STUDY ON THE PREVALENCE AND SEVERITY OF POSSIBLE DRUG-DRUG INTERACTIONS IN PEDIATRICS DEPARTMENT AT AN INDIAN TERTIARY CARE TEACHING HOSPITAL
Objective: To study the prevalence and severity of possible drug-drug interactions in the department of pediatrics.
Methods: Case records of the in-patients of the pediatrics department from the medical records department were included and the records of the ambulatory patients were excluded from the study. All the collected cases were subjected to check for the drug-drug interactions by using the software micromedex 2.0 and the interactions were categorized based on the severity into minor, moderate and major.
Results: A total of 142 cases were screened for possible drug-drug interactions (DDIs) and among them 76 cases were observed to be with possible DDIs.Â The prevalence was found to be 53.5% in this study. Majority of the cases with possible DDIs were observed to be in females. Results of the age wise categorization revealed that majority of the possible DDIS were observed in children (2-12 y) followed by the infants (1 moâ€“2 y). The drug combinations amikacin+ampicillin, paracetamol+phenytoin and ofloxacin+ondansetron were found to be the frequently observed possible DDIs of minor, moderate and major severities respectively.
Conclusion: Majority of the possible DDIs were of moderate severity followed by major. Clinical pharmacists should take the responsibility in assisting the pediatricians for screening the possible DDIs in the prescriptions there by preventing them and providing a better pharmaceutical care for the pediatric population.
2. Edisa T, Nurka P, Lejla B, Fahir B. Prevalence of polypharmacy and drug interaction among hospitalized patients: opportunities and responsibilities in pharmaceutical care. Mat Soc Med 2012;24:68-72.
3. Bergman U, Wiholm BE. Drug-related problems causing admission to a medical clinic. Eur J Clin Pharmacol 1981;20:193â€“200.
4. Koh Y, Moldeen Kutty FB, Chuen LS. Drug-related problems in hospitalized patients on polypharmacy: the influence of age and gender. Ther Clin Risk Manag 2005;1:39-48.
5. Beijer HJM, De Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): A meta-analysis of observational studies. Pharm World Sci 2002;24:46â€“54.
6. Brennan TA, Leape LL, Laird NM. The incidence of adverse drug events and negligence in hospitalized patients: results of harvard medical practice study I. N Engl J Med 1991;324:370â€“6.
7. Classen DC, Pestotnik SL, Evans RS. Adverse drug events in hospitalized patients. Excess length of stay, extra costs and attributable mortality. JAMA 1997;277:301â€“6.
8. Reimche L, Forster AJ, van Walraven C. Incidence and contributors to potential drug-drug interactions in hospitalized patients. J Clin Pharmacol 2011;51:1043-50.
9. Straubhaar B, Krahenbuhl S, Schlienger RG. The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge. Drug Saf 2006;29:79-90.
10. Athira Jith, Chaithanya T Kumar, Joffey Sara Joy, Kavitha Samy P, Sambath Kumar R. A prospective study of drug-drug interactions and adverse drug reactions among stroke patients in a tertiary care hospital. Asian J Pharm Clin Res 2016;9 Suppl 3:100-4.
11. Qorraj Bytyqi H, Hoxha R, Krasniqi S, Bahtiri E, Kransiqi V. The incidence and clinical relevance of drug interactions in paediatrics. J Pharmacol Pharmacother 2012Í¾ 3:3047.
12. Tom Revzon C. Drug Interactions. Pediatr Rev 2006;27:315-7.
13. Puckett WH Jr, Visconti JA. An epidemiologic study of the clinical significance of drug-drug interactions in a private community hospital. Am J Hosp Pharm 1971;28:247-53.
14. Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, et al. The nature of adverse events in hospitalized patients. Results from the Harvard Medical Practice Study II. N Engl J Med 1991;324:377-84.
15. Tatro DS. Drug interaction facts. St. Louis: Facts and Comparison; 2004.
16. Mohammad Ismail, Zafar Iqbal, Muhammad I Khan, Arshad Javaid, Hassan Arsalan, Farhadullah, et al. Frequency, levels and predictors of potential drug-drug interactions in a paediatrics ward of a teaching hospital in Pakistan. Trop J Pharm Res 2013;12:401-6.
17. Ismail M, Iqbal Z, Khattak MB, Javaid A, Khan MI, Khan TM. Potential drug-drug interactions in cardiology ward of a teaching hospital. Healthmed 2012;6:1618-24.
18. Van Leeuwen RW, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol 2011;22:2334-41.
19. Ismail M, Iqbal Z, Khattak MB, Javaid A, Khan MI, Khan TM, et al. Potential drug-drug interactions in psychiatric ward of a tertiary care hospital: prevalence, levels and association with risk factors. Trop J Pharm Res 2012;11:289-96.
20. Mateti UV, Rajakannan T, Nekkanti H, Rajesh V, Mallaysamy SR, Ramachandran P. Drug-drug interactions in hospitalized cardiac patients. J Young Pharmacists 2011;3:329-33.
21. Reis AM, Cassiani SH. Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clinics 2011;66:9-15.
22. Ismail M, Iqbal Z, Khattak MB, Javaid A, Khan TM. Prevalence, types and predictors of potential drug-drug interactions in pulmonology ward of a tertiary care hospital. Afr J Pharm Pharmacol 2011;5:1303-9.
23. Hoffmann W, Van Den Berg N, Thyrian JR, Fiss T. Frequency and determinants of potential drug-drug interactions in an elderly population receiving regular home visits by GPs-results of the home medication review in the AGnES-studies. Pharmacoepidemiol Drug Saf 2011;20:1311-8.
24. Ramam S, Suresh Kumar SV, Devanna N, Ravindra Reddy K. Prevalence and severity of possible drug-drug interactions in the inpatient department of internal medicine. Int J Pharm Clin Res 2016;8:1212-4.
25. Qorraj Bytyqi H, Hoxha R, Krasniqi S, Bahtiri E, Kransiqi V. The incidence and clinical relevance of drug interactions in paediatrics. J Pharmacol Pharmacother 2012;3:304-7.